EP4398913A1 - Contraceptive regimen including reduced level of estrogen - Google Patents

Contraceptive regimen including reduced level of estrogen

Info

Publication number
EP4398913A1
EP4398913A1 EP22782576.7A EP22782576A EP4398913A1 EP 4398913 A1 EP4398913 A1 EP 4398913A1 EP 22782576 A EP22782576 A EP 22782576A EP 4398913 A1 EP4398913 A1 EP 4398913A1
Authority
EP
European Patent Office
Prior art keywords
mcg
estrogen
consecutive days
progestogen
regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22782576.7A
Other languages
German (de)
French (fr)
Inventor
Roger M. Boissonneault
Ryan Loughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millicent Pharma Ltd
Original Assignee
Millicent Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/483,199 external-priority patent/US20230070977A1/en
Application filed by Millicent Pharma Ltd filed Critical Millicent Pharma Ltd
Publication of EP4398913A1 publication Critical patent/EP4398913A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Definitions

  • This invention is related to regimens that include a progestogenic and estrogenic components that can be used for contraception and provide not only significantly less estrogen daily, but also significantly less overall estrogen in the regimen without compromising contraceptive efficacy, cycle control, or other desired benefits. Moreover, the invention provides for regimens that are effective for contraception while reducing the risk for osteoporosis. In addition, the regimens provided herein can be used for the treatment of one or more symptoms associated with endometriosis or fibroids. Also provided is a kit that may be used to practice the aforementioned inventive regimens.
  • Contraceptive compositions typically contain both estrogenic and progestogenic compounds and are known to be highly effective in controlling ovulation.
  • the progestogenic component of the composition is primarily responsible for the contraceptive efficacy of the composition, and the estrogenic component is employed to reduce undesired side effects, such as breakthrough bleeding, spotting, or bone loss.
  • 4,962,098 discloses a triphasic method of contraception using a progestogen/estrogen combination in which the amount of estrogen is increased stepwise over the three phases.
  • the progestogen is 0.5 to 1.5 mg of norethindrone acetate, while about 10 to 30 mcg of ethinyl estradiol is used in the first phase, about 20 to 40 mcg of ethinyl estradiol is used in the second phase and 30 to 50 mcg of ethinyl estradiol is employed in the third phase.
  • Other multiphasic contraceptive compositions have been described in U.S. Patent Nos. 8,461,138 and 8,124,595.
  • mini-pills only contains progestogen component in the absence of the estrogenic component. While this may not have certain drawbacks associated with estrogen exposure, it is known to induce bone loss and have less contraceptive efficacy than that of a combined estrogenic/progestogenic contraceptive composition.
  • the invention provides both cyclic and continuous methods of contraception that make it possible to significantly reduce not only the daily amount of estrogen administered, but also the overall amount of estrogen administered, while still achieving desired contraceptive efficacy and controlling undesired side effects.
  • the regimens disclosed herein can be used for the treatment of one or more symptoms associated with endometriosis or fibroids.
  • This invention is related to a method of contraception for a female in need thereof.
  • the method is a cyclic monophasic method and comprises the step of: administering, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28-day cycle.
  • the method comprises the step of administering, daily, a placebo for a remainder of the 28- day cycle.
  • the method is a cyclic multiphasic method and comprises the steps of: administering, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 26 consecutive days of a 28- day cycle; and administering, daily, about 1 mcg to less than about 5 mcg of the estrogen in the absence of the progestogen for about 1 to about 6 consecutive days, of the 28-day cycle following the preceding step.
  • the method comprises the step of administering, daily, a placebo for a remainder of the 28-day cycle.
  • the method is a cyclic monophasic method and comprises the step of: administering, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for at least about 28 consecutive days up to about 84 consecutive days of a cycle.
  • the method comprises the step of administering, daily, a placebo for about 1 to 7 consecutive days of the cycle.
  • the method is monophasic continuous method and comprises the step of administering, daily about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen.
  • the regimens disclosed herein can be used for contraception, which, in addition to providing desired contraceptive efficacy, can control undesired side effects associated with conventional contraceptive regimens.
  • the regimens disclosed herein can also provide effective treatment or prevention of symptoms related to endometriosis or fibroids, such as pain and heavy bleeding. As a result, there is no need for a separate treatment of these symptoms, such as conventionally prescribed GnRH antagonists or agonists.
  • GnRH antagonists such as elagolix
  • GnRH antagonists are typically prescribed for the management of moderate to severe pain associated with endometriosis in pre-menopausal females.
  • these GnRH antagonists reduce endogenous sex hormones, such as estrogens, to post-menopausal levels. This can lead to a reduction in bone density, the occurrence of post-menopausal vasomotor systems, such as hot flashes or night sweats, and other urogenital symptoms.
  • combinations of an estrogen and progestogen are often prescribed concomitantly with GnRH antagonists to treat the side effects of pharmacologically induced menopause, and since GnRH antagonists are not prescribed for contraception.
  • An alternative available contraceptive regimen is, for example, a so-called “minipill,” which only includes a progestogenic component in order to avoid some of the drawbacks associated with estrogen exposure.
  • a mini -pill may be prescribed to females who are breast-feeding.
  • doctors may prescribe the mini-pill rather than a conventional contraceptive regimen, since conventional contraceptive regimens are not recommended to be prescribed with conditions such as high blood pressure, cardiovascular issue, as well as issues with mobility.
  • the present invention provides estrogenic/progestogenic regimens that use a significantly lower amount of estrogenic component than conventional contraceptive regimens, yet provide more benefits than the “mini-pill.”
  • the endometrial tissue stimulation can be reduced or minimized.
  • the regimens disclosed herein can be used not only for contraception, but also to treat the symptoms associated with endometriosis and/or fibroids without the need for administering a conventional treatment, such as a GnRH antagonist or agonist.
  • the overall significantly reduced level of estrogenic compound exposure only minimally contributes to bone loss and, surprisingly, may have little to no effect on suppression of lactation.
  • regimens that allow for safe, effective and long-term use without a placebo, which can eliminate the withdrawal bleed, and allows for a female to remain on the same regimen, without needing to switch to, for example, a mini-pill, when closer in age to perimenopause or menopause.
  • the regimens disclosed herein are also safe and effective for females who may have cardiovascular issues and/or high blood pressure.
  • the designation “mcg” refers to micrograms and “mg” to milligrams.
  • administration refers to oral administration. That is, the methods/regimens disclosed herein pertain to oral administrations.
  • female in need thereof refers to a female of child-bearing age, and may be experiencing one or more symptoms associated with endometriosis or fibroids.
  • the female in need thereof is a female who has started menstruation and/or is sexually active but is not yet in menopause.
  • the female in need thereof is premenopausal or peri-menopausal, but not in menopause, such that the age range may be about 14 years old to about 55 years old, depending on the individual.
  • continuous refers to the uninterrupted time period of hormone administration in which there are no hormonal component-free intervals (i.e., placebo periods). Thus, a continuous period, which may be up to about 40 years, does not have a time interval which induces a withdrawal bleed for the duration of the method.
  • the symptoms associated with endometriosis or fibroids include, for example, pain, menstrual symptoms, gastrointestinal symptoms, abdominal symptoms, and infertility. Pain associated with endometriosis can include, for example, lower abdominal pain, lower back pain, pelvic pain, rectal pain, and vaginal pain. Pain associated with endometriosis can also include, for example, pain during sexual intercourse, pain during defecation, and pain during urination. Menstrual symptoms associated with endometriosis can include, for example, abnormal menstruation, heavy menstruation, irregular menstruation, prolonged menstruation, painful menstruation, and spotting. Gastrointestinal symptoms associated with endometriosis include, for example, diarrhea, constipation, and nausea.
  • Abdominal symptoms associated with endometriosis can include, for example, abdominal fullness and cramping.
  • One of ordinary skill in the art would recognize that the amount of pain the female in need thereof experiences does not necessarily correlate with the severity of endometriosis.
  • the female in need thereof having a moderate or severe degree of endometriosis may experience minimal or no pain.
  • the female in need thereof having a mild degree of endometriosis may experience moderate or severe pain or other aforementioned symptoms associated with endometriosis.
  • Endometriosis can be located in various parts of the female in need thereof, including, for example, ovaries, fallopian tubes, uterosacral ligaments, posterior cul-de-sac (space between the uterus and rectum), anterior cul-de-sac (space between the uterus and bladder), outer surface of the uterus, lining of the pelvic cavity, intestines, rectum, bladder, vagina, cervix, vulva, and abdominal surgery scars.
  • Estrogens which may be used in the present invention include, for example, ethinyl estradiol, 17[3-estradiol, 17[3-estradiol-3 -acetate, mestranol, conjugated estrogens, USP and estrone or salts thereof.
  • the estrogen is ethinyl estradiol.
  • the amount of estrogen used is described herein as that which is “equivalent” in estrogenic potency to an amount of ethinyl estradiol.
  • the equivalent estrogenic potency of an estrogen to ethinyl estradiol may be readily determined by one of ordinary skill in the art.
  • Progestogens which may be used in the present invention include, for example, progesterone and its derivatives such as 17-hydroxy progesterone esters and 19-nor-17- hydroxy progesterone esters, 17-alpha-ethinyl testosterone, 17-alpha-ethinyl-19- nortestosterone (norethindrone) and derivatives thereof, norethindrone acetate, norgestrel, nogestamate, desogestrel and D-17-beta-acetoxy-17-beta-ethyl-17-alpha-ethinyl-gon-4-en- 3-one oxime.
  • progesterone and its derivatives such as 17-hydroxy progesterone esters and 19-nor-17- hydroxy progesterone esters, 17-alpha-ethinyl testosterone, 17-alpha-ethinyl-19- nortestosterone (norethindrone) and derivatives thereof, norethindrone acetate,
  • progestogens include demegestone, drospirenone, dydroge sterone, gestodene, medrogestone, medroxy progesterone and esters thereof.
  • the amount of progestogen used is described herein as that which is “equivalent” in progestogenic potency to an amount of norethindrone acetate.
  • the equivalent progestogenic potency of a progestogen to norethindrone acetate may be readily determined by one of ordinary skill in the art.
  • a placebo may be skipped altogether so that neither the active ingredients nor a placebo composition (e.g., a sugar tablet) is administered. That is, a reference to the administration of a placebo herein also encompasses skipping altogether the active ingredients and the placebo composition.
  • a placebo composition e.g., a sugar tablet
  • the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28- day cycle; and (b) a placebo for the remainder of the 28 -day cycle.
  • the administration period for this monophasic cyclic contraceptive method is based on a 28-day cycle.
  • a new cycle begins following the completion of the preceding cycle.
  • a new 28-day cycle begins following the completion of the preceding 28-day cycle.
  • the new cycle and the preceding cycle are identical in the number of days
  • the estrogen is administered in a daily amount of about 1.0 mcg to less than about 5.0 mcg. In an embodiment, the estrogen is administered in a daily amount of about 2.0 mcg to about 4.0 mcg, or about 2.25 mcg to about 3.5 mcg, or about 2.25 mcg to about 3.0 mcg. In an embodiment, the estrogen is administered in a daily amount of about 1 mcg, or about 1.
  • the estrogen is administered in a daily amount of 2.5 mcg.
  • the progestogen is administered in a daily amount of about 0.075 mg to about 5.0 mg, or about 0.3 mg to about 5.0 mg. In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg to about 4.0 mg, or about 0.075 mg to about 2.0 mg, or about 0.075 mg to about 1.0 mg, or about 0.075 mg to about 0.15 mg, or about 0.4 mg to about 4.0 mg, or about 0.4 mg to about 3.0 mg, or about 0.5 mg to about 2 mg.
  • the progestogen is administered in a daily amount of about 0.075 mg, or about 0.1 mg, or about 0.15 mg, or about 0.2 mg, or about 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1. 1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg, or any amount in between.
  • the progestogen is administered in a daily amount of about 1.0 mg.
  • the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 27 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 1 day of the 28-day cycle.
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen.
  • the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate.
  • the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0. 15 mg of a desogestrel.
  • the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 26 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 2 days of the 28-day cycle.
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen.
  • the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate.
  • the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 25 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 3 days of the 28-day cycle.
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen.
  • the composition comprises 2.5 mcg of ethinyl estradiol and 1 mg of norethindrone acetate.
  • the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 24 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 4 days of the 28-day cycle.
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen.
  • the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate.
  • the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 23 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 5 days of the 28-day cycle.
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen.
  • the composition comprises 2.5 mcg of ethinyl estradiol and 1 mg of norethindrone acetate.
  • the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 22 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 6 days of the 28-day cycle.
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen.
  • the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate.
  • the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 21 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 7 days of the 28-day cycle.
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen.
  • the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate.
  • the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 20 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 8 days of the 28-day cycle.
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen.
  • the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate.
  • the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for at least 28 consecutive days up to about 84 consecutive days of a cycle; and (b) a placebo for about 1 to about 7 days following step (a) for the remainder of the cycle.
  • the administration period for this cyclic monophasic regimen has an administration period of up to 91 days.
  • a new cycle begins following the completion of the preceding cycle.
  • a new 63-day begins following the completion of the preceding 63-day cycle.
  • the new cycle and the preceding cycle are identical in the number of days.
  • the estrogen is administered in a daily amount of about 1.0 mcg to less than about 5.0 mcg. In an embodiment, the estrogen is administered in a daily amount of about 2.0 mcg to about 4.0 mcg, or about 2.25 mcg to about 3.5 mcg, or about 2.25 mcg to about 3.0 mcg.
  • the estrogen is administered in a daily amount of about 1 mcg, or about 1.1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2.
  • the estrogen is administered in a daily amount of 2.5 mcg.
  • the progestogen is administered in a daily amount of about 0.075 mg to about 5.0 mg, or about 0.3 mg to about 5.0 mg. In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg to about 4.0 mg, or about 0.075 mg to about 2.0 mg, or about 0.075 mg to about 1.0 mg, or about 0.075 mg to about 0.15 mg, or about 0.4 mg to about 4.0 mg, or about 0.4 mg to about 3.0 mg, or about 0.5 mg to about 2 mg.
  • the progestogen is administered in a daily amount of about 0.075 mg, or about 0.1 mg, or about 0.15 mg, or about 0.2 mg, or about 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1. 1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg, or any amount in between.
  • the progestogen is administered in a daily amount of about 1.0 mg.
  • the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for at least 28 consecutive days, or about 42 days, or about 56 days, or about 63 days, up to about 84 consecutive days; and (b) a placebo for about 1 to about 7 days following step (a).
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen.
  • the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the method of contraception for a female in need thereof is a cyclic multiphasic regimen which includes administering, daily, the following: (a) phase I composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for any one of about 20 to about 26 consecutive days of a 28-day cycle; (b) phase II composition comprising about 1 mcg to less than about 5 mcg of the estrogen, without a progestogen, for about 1 to about 6 consecutive days of the 28-day cycle following the administration of the phase I composition, such that at least one day remains in this 28-day cycle; and (c) a placebo for the remainder of the 28-day cycle.
  • phase I composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for any one of about 20 to about 26 consecutive days of a 28-day cycle
  • phase II composition comprising about 1
  • the phase I composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the phase II composition comprises about 2.5 mcg of an estrogen. In an embodiment, the phase II composition comprises about 2.5 mcg of ethinyl estradiol.
  • the administration period for this multiphasic cyclic contraceptive method is based on a 28 -day cycle. In an embodiment, a new cycle begins following the completion of the preceding cycle. For example, a new 28-day cycle begins following the completion of the preceding 28-day cycle. In an embodiment, the new cycle and the preceding cycle are identical in the number of days.
  • the estrogen in each of phases I and II is administered in a daily amount of about 1.0 mcg to less than about 5.0 mcg. In an embodiment, the estrogen in each of phases I and II is administered in a daily amount of about 2.0 mcg to about 4.0 mcg, or about 2.25 mcg to about 3.5 mcg, or about 2.25 mcg to about 3.0 mcg.
  • the estrogen in each of phases I and II is administered in a daily amount of about 1 mcg, or about 1.1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1 .8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2.
  • the progestogen in phase I is administered in a daily amount of about 0.075 mg to about 5.0 mg, or about 0.3 mg to about 5.0 mg. In an embodiment, the progestogen in phase I is administered in a daily amount of about 0.075 mg to about 4.0 mg, or about 0.075 mg to about 2.0 mg, or about 0.075 mg to about 1.0 mg, or about 0.075 mg to about 0.15 mg, or about 0.4 mg to about 4.0 mg, or about 0.4 mg to about 3.0 mg, or about 0.5 mg to about 2 mg. In an embodiment, the progestogen in phase I is administered in a daily amount of about 0.075 mg, or about 0.
  • the progestogen in phase I is administered in a daily amount of about 1.0 mg. In an embodiment, no progestogen is administered in phase II.
  • the method of contraception for a female in need thereof is a cyclic multiphasic regimen which includes administering, daily, the following compositions: (a) phase I composition for 24 consecutive days of a 28-day cycle comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen; (b) phase II composition for 2 consecutive days of the 28-day cycle following the administration of the phase I composition, comprising about 1 mcg to less than about 5 mcg of the estrogen without a progestogen; and (c) a placebo for 2 consecutive days of the 28-day cycle following the administration of the phase II composition.
  • the phase I composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0. 15 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel. In an embodiment, the phase II composition comprises about 2.5 mcg of an estrogen. In an embodiment, the phase II composition comprises about 2.5 mcg of ethinyl estradiol.
  • the method of contraception for a female in need thereof is a cyclic multiphasic regimen which includes administering, daily, the following compositions: (a) phase I composition for 24 consecutive days of a 28-day cycle comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen; (b) phase II composition for 3 consecutive days of the 28-day cycle following the administration of the phase I composition, comprising about 1 mcg to less than about 5 mcg of the estrogen without a progestogen; and (c) a placebo for 1 day of the 28-day cycle following the administration of the phase II composition.
  • the phase I composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0. 15 mg of a desogestrel. In an embodiment, the phase II composition comprises about 2.5 mcg of an estrogen. In an embodiment, the phase II composition comprises about 2.5 mcg of ethinyl estradiol.
  • the method of contraception for a female in need thereof is a cyclic multiphasic regimen which includes administering, daily, the following compositions: (a) phase I composition for 24 consecutive days of a 28-day cycle comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen; (b) phase II composition for 1 day of the 28-day cycle following the administration of the phase I composition, comprising about 1 mcg to less than about 5 mcg of the estrogen without a progestogen; and (c) a placebo for 3 consecutive days of the 28- day cycle following the administration of the phase II composition, comprising a.
  • the phase I composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel. In an embodiment, the phase II composition comprises about 2.5 mcg of an estrogen. In an embodiment, the phase II composition comprises about 2.5 mcg of ethinyl estradiol.
  • the method of contraception for a female in need thereof is a monophasic continuous regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen.
  • the estrogen is administered in a daily amount of about 1.0 mcg to less than about 5.0 mcg. In an embodiment, the estrogen is administered in a daily amount of about 2.0 mcg to about 4.0 mcg, or about 2.25 mcg to about 3.5 mcg, or about 2.25 mcg to about 3.0 mcg. In an embodiment, the estrogen is administered in a daily amount of about 1 mcg, or about 1.
  • the estrogen is administered in a daily amount of 2.5 mcg.
  • the progestogen is administered in a daily amount of about 0.075 mg to about 5.0 mg, or about 0.3 mg to about 5 mg. In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg to about 4.0 mg, or about 0.075 mg to about 2.0 mg, or about 0.075 mg to about 1.0 mg, or about 0.075 mg to about 0.15 mg, or about 0.4 mg to about 4.0 mg, or about 0.4 mg to about 3.0 mg, or about 0.5 mg to about 2 mg.
  • the progestogen is administered in a daily amount of about 0.075 mg, or about 0.1 mg, or about 0.15 mg, or about 0.2 mg, or about 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1. 1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg, or any amount in between.
  • the progestogen is administered in a daily amount of about 1.0 mg.
  • the estrogen and the progestogen can be in a combined single dosage form or a separate dosage form.
  • the dosage form can be a solid dosage form, a liquid dosage form, or a semisolid dosage form.
  • the dosage form can include, for example, a pill, an orally disintegrating tablet, a chewable tablet, a swallowing tablet, a capsule, a caplet, a drink, a syrup, a gel, or a strip.
  • the dosage form is a vaginal ring or a patch, such that the vaginal ring or patch can be removed during any period where the active ingredient(s) are not administered in the methods disclosed herein.
  • a patch or ring can be removed after a defined period (e.g., 90 days) and another ring or patch can be applied right away so as to provide uninterrupted administration of the active ingredient(s).
  • the contraception method includes a kit comprising a package containing daily dosages of the estrogen with or without the progestogen, and the optional placebo, as described herein.
  • the package may contain daily dosages of: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28-day cycle (e.g., about 20 to about 27 tablets, each including the aforementioned amounts of the estrogen and the progestogen, in, for example, a blister pack); and (b) a placebo (e.g., placebo tablet(s) in, for example, the blister pack, or, alternatively, empty blister(s) in the blister pack) for the remainder of the 28-day cycle.
  • a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28-day cycle (e.g., about 20 to about 27 tablets, each including the aforementioned amounts of the estrogen and the progestogen, in, for example, a blister pack);
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the kit further comprises instructions for administering the daily dosages according to the method of contraception for a female in need thereof, being a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28- day cycle; and (b) a placebo for the remainder of the 28 -day cycle.
  • a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28- day cycle
  • a placebo for the remainder of the 28 -day cycle.
  • the package may contain daily dosages of: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 28 consecutive days up to 84 consecutive days (e.g., up to 84 tablets, each including the aforementioned amounts of the estrogen and the progestogen, in, for example, a blister pack, or multiple blister packs); and (b) a placebo (e.g., placebo tablet(s) in, for example, the blister pack, or, alternatively, empty blister(s) in the blister pack) for the up to 7 days.
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen.
  • the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the kit further comprises instructions for administering the daily dosages according to the method of contraception for a female in need thereof, being a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for at least 28 consecutive days up to about 84 consecutive days of a cycle; and (b) a placebo for about 1 to about 7 days following step (a) for the remainder of the cycle.
  • a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for at least 28 consecutive days up to about 84 consecutive days of a cycle
  • a placebo for about 1 to about 7 days following step (a) for the remainder of the cycle.
  • the package may contain daily dosages of: (a) phase I composition comprising about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 26 consecutive days of a 28-day cycle (e.g., about 20 to about 26 tablets, each including the aforementioned amounts of the estrogen and the progestogen, in, for example, a blister pack); (b) phase II composition comprising about 1 mcg to less than about 5 mcg of the estrogen, without a progestogen, for about 1 to about 6 consecutive days of the 28-day cycle following the administration of the phase I composition, such that at least one day remains in this 28-day cycle (e.g., about 1 to 6 tablets, each including the aforementioned amount of the estrogen and no progestogen, in, for example, the blister pack); and (c) a placebo (e.g., placebo tablet(s), or, alternatively, empty blister(s) in the blister pack
  • a placebo e
  • the phase I composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel. In an embodiment, the phase II composition comprises about 2.5 mcg of an estrogen. In an embodiment, the phase II composition comprises about 2.5 mcg of ethinyl estradiol.
  • the kit further comprises instructions for administering the daily dosages according to the method of contraception for a female in need thereof, being a cyclic multiphasic regimen which includes administering, daily, the following compositions: (a) phase I composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for about 20 to about 26 consecutive days of a 28-day cycle; (b) phase II composition comprising about 1 mcg to less than about 5 mcg of the estrogen in the absence of the progestogen for about 1 to about 6 consecutive days of the 28-day cycle following the administration of the phase I composition,; and (c) a placebo for the remainder of the 28-day cycle following the administration of the phase II composition.
  • phase I composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for about 20 to about 26 consecutive days of a 28-day cycle
  • the package may contain daily dosages of: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for a continuous regimen.
  • the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen.
  • the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate.
  • the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen.
  • the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
  • the kit further comprises instructions for administering the daily dosages according to the method of contraception for a female in need thereof, being a monophasic continuous regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen.
  • compositions in a numeric sequence with the estrogen/progestin containing composition(s) being used first, optionally, the estrogen only composition(s) or the optional placebo being used thereafter as discussed above, if packaging and/or other requirements dictate, the method and kit described herein can be employed as part of a larger scheme for contraception, or treatment of gynecological disorders.
  • Reasonable variations such as those which would occur to one of ordinary skill in the art, can be made herein without departing from the scope of the invention. For example, variations in time and dosage can be tolerated when medical considerations so dictate.
  • compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
  • NA norethindrone acetate
  • EE ethinyl estradiol
  • compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
  • NA norethindrone acetate
  • EE ethinyl estradiol
  • compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
  • NA norethindrone acetate
  • EE ethinyl estradiol
  • compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
  • phase I composition is administered as oral dosage forms.
  • phase II composition is administered as an oral dosage form.
  • compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table. [0078] Table 5
  • NA norethindrone acetate
  • EE ethinyl estradiol
  • compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
  • NA norethindrone acetate
  • EE ethinyl estradiol
  • compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
  • compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
  • NA norethindrone acetate
  • EE ethinyl estradiol
  • compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
  • norethindrone acetate (NA) and ethinyl estradiol (EE) are well known and readily available. For example, continuous regimen can be administered for up to 40 years.
  • the regimens in the above Examples are administered daily via oral dosage forms.
  • norethindrone acetate (NA) and/or ethinyl estradiol (EE) in the Examples are administered via a vaginal ring or a patch.
  • phase I is administered via a vaginal ring or a patch and phase II is administered via an oral dosage form.
  • each phase is administered via a vaginal ring or a patch.
  • the vaginal ring may be removed after a certain period of time (e.g., 30 days or 90 days) followed by immediately inserting a new vaginal ring.
  • the patch may be removed after a certain period of time (e.g., 30 days or 90 days) followed by immediately applying a new patch.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A contraceptive regimen that provides for a reduced level of estrogen. The contraceptive regimen can be used for the treatment of symptoms associated with endometriosis or fibroids.

Description

TITLE
CONTRACEPTIVE REGIMEN INCLUDING REDUCED LEVEL OF ESTROGEN
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the benefit of U.S. Provisional Application No. 63/241,178, filed September 7, 2021 and U.S. Application No. 17/483,199, filed September 23, 2021, which itself claims the benefit of U.S. Provisional Application No. 63/241,178. The entirety of each of these prior applications is here incorporated by reference herein.
FIELD OF THE INVENTION
[0002] This invention is related to regimens that include a progestogenic and estrogenic components that can be used for contraception and provide not only significantly less estrogen daily, but also significantly less overall estrogen in the regimen without compromising contraceptive efficacy, cycle control, or other desired benefits. Moreover, the invention provides for regimens that are effective for contraception while reducing the risk for osteoporosis. In addition, the regimens provided herein can be used for the treatment of one or more symptoms associated with endometriosis or fibroids. Also provided is a kit that may be used to practice the aforementioned inventive regimens.
BACKGROUND OF THE INVENTION
[0003] Contraceptive compositions typically contain both estrogenic and progestogenic compounds and are known to be highly effective in controlling ovulation. The progestogenic component of the composition is primarily responsible for the contraceptive efficacy of the composition, and the estrogenic component is employed to reduce undesired side effects, such as breakthrough bleeding, spotting, or bone loss.
[0004] Earlier forms of estrogenic/progestogenic contraceptive compositions (monophasic or multiphasic) contained a relatively high level of estrogenic component. Over time estrogenic/progestogenic contraceptive compositions have been disclosed where the amount of estrogen of such compositions has been lowered without reducing contraceptive efficacy and/or increasing undesired side effects. U.S. Patent No. 5,888,543, discloses progestogen/estrogen combinations in a monophasic regimen (fixed dose in the cycle) or as biphasic or triphasic regimens (varied dose over the cycle). [0005] U.S. Patent No. 4,962,098 discloses a triphasic method of contraception using a progestogen/estrogen combination in which the amount of estrogen is increased stepwise over the three phases. For all three phases the progestogen is 0.5 to 1.5 mg of norethindrone acetate, while about 10 to 30 mcg of ethinyl estradiol is used in the first phase, about 20 to 40 mcg of ethinyl estradiol is used in the second phase and 30 to 50 mcg of ethinyl estradiol is employed in the third phase. Other multiphasic contraceptive compositions have been described in U.S. Patent Nos. 8,461,138 and 8,124,595.
[0006] Alternatively, another form of contraception, known as “mini-pills” only contains progestogen component in the absence of the estrogenic component. While this may not have certain drawbacks associated with estrogen exposure, it is known to induce bone loss and have less contraceptive efficacy than that of a combined estrogenic/progestogenic contraceptive composition.
SUMMARY OF THE INVENTION
[0007] The invention provides both cyclic and continuous methods of contraception that make it possible to significantly reduce not only the daily amount of estrogen administered, but also the overall amount of estrogen administered, while still achieving desired contraceptive efficacy and controlling undesired side effects. In addition, the regimens disclosed herein can be used for the treatment of one or more symptoms associated with endometriosis or fibroids.
[0008] This invention is related to a method of contraception for a female in need thereof. In an embodiment, the method is a cyclic monophasic method and comprises the step of: administering, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28-day cycle. The method comprises the step of administering, daily, a placebo for a remainder of the 28- day cycle.
[0009] In an embodiment, the method is a cyclic multiphasic method and comprises the steps of: administering, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 26 consecutive days of a 28- day cycle; and administering, daily, about 1 mcg to less than about 5 mcg of the estrogen in the absence of the progestogen for about 1 to about 6 consecutive days, of the 28-day cycle following the preceding step. The method comprises the step of administering, daily, a placebo for a remainder of the 28-day cycle. [0010] In an embodiment, the method is a cyclic monophasic method and comprises the step of: administering, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for at least about 28 consecutive days up to about 84 consecutive days of a cycle. The method comprises the step of administering, daily, a placebo for about 1 to 7 consecutive days of the cycle.
[0011] In an embodiment, the method is monophasic continuous method and comprises the step of administering, daily about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen.
DETAILED DESCRIPTION OF THE INVENTION
[0012] The regimens disclosed herein can be used for contraception, which, in addition to providing desired contraceptive efficacy, can control undesired side effects associated with conventional contraceptive regimens. The regimens disclosed herein can also provide effective treatment or prevention of symptoms related to endometriosis or fibroids, such as pain and heavy bleeding. As a result, there is no need for a separate treatment of these symptoms, such as conventionally prescribed GnRH antagonists or agonists.
[0013] Conventional contraceptive regimens utilize relatively high amounts of estrogen. While these amounts are less than what they were even a few decades ago, they are still sufficiently high to have the potential to cause various adverse effects. From among the currently available combined estrogenic/progestogenic contraceptive regimens, Lo Loestrin® has the lowest level of estrogen at 10 mcg of ethinyl estradiol per day. However, even this amount of estrogen can contribute to endometrial tissue stimulation and may lead to adverse effects including inflammation, severe pain, heavy or light periods, aggravated premenstrual syndrome, weight gain, noncancerous lumps in breasts, fibroids, fatigue, low sex drive, depression, or anxiety. Especially for females with endometriosis, which is a chronic disorder characterized by the implantation of endometrial glands and stroma outside the uterine cavity, these symptoms can be more severe and debilitating.
[0014] While there are different hypotheses regarding the pathogenesis of endometriosis, one conventional way to treat the symptoms of endometriosis is by administering either GnRH agonists or GnRH antagonists. For example, GnRH antagonists, such as elagolix, are typically prescribed for the management of moderate to severe pain associated with endometriosis in pre-menopausal females. However, these GnRH antagonists reduce endogenous sex hormones, such as estrogens, to post-menopausal levels. This can lead to a reduction in bone density, the occurrence of post-menopausal vasomotor systems, such as hot flashes or night sweats, and other urogenital symptoms. As a result, combinations of an estrogen and progestogen are often prescribed concomitantly with GnRH antagonists to treat the side effects of pharmacologically induced menopause, and since GnRH antagonists are not prescribed for contraception.
[0015] An alternative available contraceptive regimen is, for example, a so-called “minipill,” which only includes a progestogenic component in order to avoid some of the drawbacks associated with estrogen exposure. For example, a mini -pill may be prescribed to females who are breast-feeding. Moreover, as females begin to get closer to perimenopause or menopause, doctors may prescribe the mini-pill rather than a conventional contraceptive regimen, since conventional contraceptive regimens are not recommended to be prescribed with conditions such as high blood pressure, cardiovascular issue, as well as issues with mobility. However, the absence of estrogen altogether has its own drawbacks because an estrogenic component in a contraceptive can be helpful for decreasing the effects of bone loss, increasing stability to the endometrium, preventing irregular shedding and unwanted breakthrough bleeding as well as increasing the potency of the progestogenic component including in its antifertility effects.
[0016] In contrast, the present invention provides estrogenic/progestogenic regimens that use a significantly lower amount of estrogenic component than conventional contraceptive regimens, yet provide more benefits than the “mini-pill.” Advantageously, as a result of the reduction in the overall level of estrogenic compound exposure over the complete cycle, the endometrial tissue stimulation can be reduced or minimized. Thus, the regimens disclosed herein can be used not only for contraception, but also to treat the symptoms associated with endometriosis and/or fibroids without the need for administering a conventional treatment, such as a GnRH antagonist or agonist. In addition, the overall significantly reduced level of estrogenic compound exposure only minimally contributes to bone loss and, surprisingly, may have little to no effect on suppression of lactation. Furthermore, described herein are regimens that allow for safe, effective and long-term use without a placebo, which can eliminate the withdrawal bleed, and allows for a female to remain on the same regimen, without needing to switch to, for example, a mini-pill, when closer in age to perimenopause or menopause. The regimens disclosed herein are also safe and effective for females who may have cardiovascular issues and/or high blood pressure.
[0017] The designation “mcg” refers to micrograms and “mg” to milligrams. [0018] The term “administration” refers to oral administration. That is, the methods/regimens disclosed herein pertain to oral administrations. [0019] The term “female in need thereof’ refers to a female of child-bearing age, and may be experiencing one or more symptoms associated with endometriosis or fibroids. For example, the female in need thereof is a female who has started menstruation and/or is sexually active but is not yet in menopause. Thus, the female in need thereof is premenopausal or peri-menopausal, but not in menopause, such that the age range may be about 14 years old to about 55 years old, depending on the individual.
[0020] The term “continuous” refers to the uninterrupted time period of hormone administration in which there are no hormonal component-free intervals (i.e., placebo periods). Thus, a continuous period, which may be up to about 40 years, does not have a time interval which induces a withdrawal bleed for the duration of the method.
[0021] The symptoms associated with endometriosis or fibroids include, for example, pain, menstrual symptoms, gastrointestinal symptoms, abdominal symptoms, and infertility. Pain associated with endometriosis can include, for example, lower abdominal pain, lower back pain, pelvic pain, rectal pain, and vaginal pain. Pain associated with endometriosis can also include, for example, pain during sexual intercourse, pain during defecation, and pain during urination. Menstrual symptoms associated with endometriosis can include, for example, abnormal menstruation, heavy menstruation, irregular menstruation, prolonged menstruation, painful menstruation, and spotting. Gastrointestinal symptoms associated with endometriosis include, for example, diarrhea, constipation, and nausea. Abdominal symptoms associated with endometriosis can include, for example, abdominal fullness and cramping. One of ordinary skill in the art would recognize that the amount of pain the female in need thereof experiences does not necessarily correlate with the severity of endometriosis. For example, on the one hand, the female in need thereof having a moderate or severe degree of endometriosis may experience minimal or no pain. On the other hand, the female in need thereof having a mild degree of endometriosis may experience moderate or severe pain or other aforementioned symptoms associated with endometriosis.
[0022] Endometriosis can be located in various parts of the female in need thereof, including, for example, ovaries, fallopian tubes, uterosacral ligaments, posterior cul-de-sac (space between the uterus and rectum), anterior cul-de-sac (space between the uterus and bladder), outer surface of the uterus, lining of the pelvic cavity, intestines, rectum, bladder, vagina, cervix, vulva, and abdominal surgery scars.
[0023] Estrogens which may be used in the present invention include, for example, ethinyl estradiol, 17[3-estradiol, 17[3-estradiol-3 -acetate, mestranol, conjugated estrogens, USP and estrone or salts thereof. In an embodiment, the estrogen is ethinyl estradiol. The amount of estrogen used is described herein as that which is “equivalent” in estrogenic potency to an amount of ethinyl estradiol. The equivalent estrogenic potency of an estrogen to ethinyl estradiol may be readily determined by one of ordinary skill in the art.
[0024] Progestogens which may be used in the present invention include, for example, progesterone and its derivatives such as 17-hydroxy progesterone esters and 19-nor-17- hydroxy progesterone esters, 17-alpha-ethinyl testosterone, 17-alpha-ethinyl-19- nortestosterone (norethindrone) and derivatives thereof, norethindrone acetate, norgestrel, nogestamate, desogestrel and D-17-beta-acetoxy-17-beta-ethyl-17-alpha-ethinyl-gon-4-en- 3-one oxime. Other exemplary progestogens include demegestone, drospirenone, dydroge sterone, gestodene, medrogestone, medroxy progesterone and esters thereof. The amount of progestogen used is described herein as that which is “equivalent” in progestogenic potency to an amount of norethindrone acetate. The equivalent progestogenic potency of a progestogen to norethindrone acetate may be readily determined by one of ordinary skill in the art.
[0025] In the regimens discloses herein, a placebo may be skipped altogether so that neither the active ingredients nor a placebo composition (e.g., a sugar tablet) is administered. That is, a reference to the administration of a placebo herein also encompasses skipping altogether the active ingredients and the placebo composition.
[0026] In an embodiment, the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28- day cycle; and (b) a placebo for the remainder of the 28 -day cycle. The administration period for this monophasic cyclic contraceptive method is based on a 28-day cycle. In an embodiment, a new cycle begins following the completion of the preceding cycle. For example, a new 28-day cycle begins following the completion of the preceding 28-day cycle. In an embodiment, the new cycle and the preceding cycle are identical in the number of days
[0027] In an embodiment, the estrogen is administered in a daily amount of about 1.0 mcg to less than about 5.0 mcg. In an embodiment, the estrogen is administered in a daily amount of about 2.0 mcg to about 4.0 mcg, or about 2.25 mcg to about 3.5 mcg, or about 2.25 mcg to about 3.0 mcg. In an embodiment, the estrogen is administered in a daily amount of about 1 mcg, or about 1. 1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2. 1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4. 1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg, or any amount in between. In an embodiment, the estrogen is administered in a daily amount of 2.5 mcg.
[0028] In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg to about 5.0 mg, or about 0.3 mg to about 5.0 mg. In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg to about 4.0 mg, or about 0.075 mg to about 2.0 mg, or about 0.075 mg to about 1.0 mg, or about 0.075 mg to about 0.15 mg, or about 0.4 mg to about 4.0 mg, or about 0.4 mg to about 3.0 mg, or about 0.5 mg to about 2 mg. In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg, or about 0.1 mg, or about 0.15 mg, or about 0.2 mg, or about 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1. 1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg, or any amount in between. In an embodiment, the progestogen is administered in a daily amount of about 1.0 mg.
[0029] In an embodiment, the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 27 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 1 day of the 28-day cycle. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0. 15 mg of a desogestrel.
[0030] In an embodiment, the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 26 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 2 days of the 28-day cycle. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0031] In an embodiment, the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 25 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 3 days of the 28-day cycle. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises 2.5 mcg of ethinyl estradiol and 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0032] In an embodiment, the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 24 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 4 days of the 28-day cycle. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0033] In an embodiment, the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 23 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 5 days of the 28-day cycle. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises 2.5 mcg of ethinyl estradiol and 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0034] In an embodiment, the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 22 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 6 days of the 28-day cycle. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0035] In an embodiment, the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 21 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 7 days of the 28-day cycle. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0036] In an embodiment, the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for 20 consecutive days of a 28-day cycle; and (b) a placebo for the remaining 8 days of the 28-day cycle. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0037] In an embodiment, the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for at least 28 consecutive days up to about 84 consecutive days of a cycle; and (b) a placebo for about 1 to about 7 days following step (a) for the remainder of the cycle. The administration period for this cyclic monophasic regimen has an administration period of up to 91 days. In an embodiment, a new cycle begins following the completion of the preceding cycle. For example, a new 63-day begins following the completion of the preceding 63-day cycle. In an embodiment, the new cycle and the preceding cycle are identical in the number of days.
[0038] In an embodiment, the estrogen is administered in a daily amount of about 1.0 mcg to less than about 5.0 mcg. In an embodiment, the estrogen is administered in a daily amount of about 2.0 mcg to about 4.0 mcg, or about 2.25 mcg to about 3.5 mcg, or about 2.25 mcg to about 3.0 mcg. In an embodiment, the estrogen is administered in a daily amount of about 1 mcg, or about 1.1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2. 1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4. 1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg, or any amount in between. In an embodiment, the estrogen is administered in a daily amount of 2.5 mcg.
[0039] In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg to about 5.0 mg, or about 0.3 mg to about 5.0 mg. In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg to about 4.0 mg, or about 0.075 mg to about 2.0 mg, or about 0.075 mg to about 1.0 mg, or about 0.075 mg to about 0.15 mg, or about 0.4 mg to about 4.0 mg, or about 0.4 mg to about 3.0 mg, or about 0.5 mg to about 2 mg. In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg, or about 0.1 mg, or about 0.15 mg, or about 0.2 mg, or about 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1. 1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg, or any amount in between. In an embodiment, the progestogen is administered in a daily amount of about 1.0 mg.
[0040] In an embodiment, the method of contraception for a female in need thereof is a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for at least 28 consecutive days, or about 42 days, or about 56 days, or about 63 days, up to about 84 consecutive days; and (b) a placebo for about 1 to about 7 days following step (a). In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0041] In an embodiment, the method of contraception for a female in need thereof is a cyclic multiphasic regimen which includes administering, daily, the following: (a) phase I composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for any one of about 20 to about 26 consecutive days of a 28-day cycle; (b) phase II composition comprising about 1 mcg to less than about 5 mcg of the estrogen, without a progestogen, for about 1 to about 6 consecutive days of the 28-day cycle following the administration of the phase I composition, such that at least one day remains in this 28-day cycle; and (c) a placebo for the remainder of the 28-day cycle. [0042] In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0043] In an embodiment, the phase II composition comprises about 2.5 mcg of an estrogen. In an embodiment, the phase II composition comprises about 2.5 mcg of ethinyl estradiol. The administration period for this multiphasic cyclic contraceptive method is based on a 28 -day cycle. In an embodiment, a new cycle begins following the completion of the preceding cycle. For example, a new 28-day cycle begins following the completion of the preceding 28-day cycle. In an embodiment, the new cycle and the preceding cycle are identical in the number of days.
[0044] In an embodiment, the estrogen in each of phases I and II is administered in a daily amount of about 1.0 mcg to less than about 5.0 mcg. In an embodiment, the estrogen in each of phases I and II is administered in a daily amount of about 2.0 mcg to about 4.0 mcg, or about 2.25 mcg to about 3.5 mcg, or about 2.25 mcg to about 3.0 mcg. In an embodiment, the estrogen in each of phases I and II is administered in a daily amount of about 1 mcg, or about 1.1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1 .8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2. 1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4.1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg, or any amount in between. In an embodiment, the estrogen in each of phases I and II is administered in a daily amount of 2.5 mcg.
[0045] In an embodiment, the progestogen in phase I is administered in a daily amount of about 0.075 mg to about 5.0 mg, or about 0.3 mg to about 5.0 mg. In an embodiment, the progestogen in phase I is administered in a daily amount of about 0.075 mg to about 4.0 mg, or about 0.075 mg to about 2.0 mg, or about 0.075 mg to about 1.0 mg, or about 0.075 mg to about 0.15 mg, or about 0.4 mg to about 4.0 mg, or about 0.4 mg to about 3.0 mg, or about 0.5 mg to about 2 mg. In an embodiment, the progestogen in phase I is administered in a daily amount of about 0.075 mg, or about 0. 1 mg, or about 0.15 mg, or about 0.2 mg, or about 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1.1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg, or any amount in between. In an embodiment, the progestogen in phase I is administered in a daily amount of about 1.0 mg. In an embodiment, no progestogen is administered in phase II.
[0046] In an embodiment, the method of contraception for a female in need thereof is a cyclic multiphasic regimen which includes administering, daily, the following compositions: (a) phase I composition for 24 consecutive days of a 28-day cycle comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen; (b) phase II composition for 2 consecutive days of the 28-day cycle following the administration of the phase I composition, comprising about 1 mcg to less than about 5 mcg of the estrogen without a progestogen; and (c) a placebo for 2 consecutive days of the 28-day cycle following the administration of the phase II composition. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0. 15 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel. In an embodiment, the phase II composition comprises about 2.5 mcg of an estrogen. In an embodiment, the phase II composition comprises about 2.5 mcg of ethinyl estradiol.
[0047] In an embodiment, the method of contraception for a female in need thereof is a cyclic multiphasic regimen which includes administering, daily, the following compositions: (a) phase I composition for 24 consecutive days of a 28-day cycle comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen; (b) phase II composition for 3 consecutive days of the 28-day cycle following the administration of the phase I composition, comprising about 1 mcg to less than about 5 mcg of the estrogen without a progestogen; and (c) a placebo for 1 day of the 28-day cycle following the administration of the phase II composition. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0. 15 mg of a desogestrel. In an embodiment, the phase II composition comprises about 2.5 mcg of an estrogen. In an embodiment, the phase II composition comprises about 2.5 mcg of ethinyl estradiol.
[0048] In an embodiment, the method of contraception for a female in need thereof is a cyclic multiphasic regimen which includes administering, daily, the following compositions: (a) phase I composition for 24 consecutive days of a 28-day cycle comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen; (b) phase II composition for 1 day of the 28-day cycle following the administration of the phase I composition, comprising about 1 mcg to less than about 5 mcg of the estrogen without a progestogen; and (c) a placebo for 3 consecutive days of the 28- day cycle following the administration of the phase II composition, comprising a. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel. In an embodiment, the phase II composition comprises about 2.5 mcg of an estrogen. In an embodiment, the phase II composition comprises about 2.5 mcg of ethinyl estradiol.
[0049] In an embodiment, the method of contraception for a female in need thereof, is a monophasic continuous regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen.
[0050] In an embodiment, the estrogen is administered in a daily amount of about 1.0 mcg to less than about 5.0 mcg. In an embodiment, the estrogen is administered in a daily amount of about 2.0 mcg to about 4.0 mcg, or about 2.25 mcg to about 3.5 mcg, or about 2.25 mcg to about 3.0 mcg. In an embodiment, the estrogen is administered in a daily amount of about 1 mcg, or about 1. 1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2. 1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4. 1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg, or any amount in between. In an embodiment, the estrogen is administered in a daily amount of 2.5 mcg.
[0051] In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg to about 5.0 mg, or about 0.3 mg to about 5 mg. In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg to about 4.0 mg, or about 0.075 mg to about 2.0 mg, or about 0.075 mg to about 1.0 mg, or about 0.075 mg to about 0.15 mg, or about 0.4 mg to about 4.0 mg, or about 0.4 mg to about 3.0 mg, or about 0.5 mg to about 2 mg. In an embodiment, the progestogen is administered in a daily amount of about 0.075 mg, or about 0.1 mg, or about 0.15 mg, or about 0.2 mg, or about 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1. 1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg, or any amount in between. In an embodiment, the progestogen is administered in a daily amount of about 1.0 mg.
[0052] In an embodiment, the estrogen and the progestogen can be in a combined single dosage form or a separate dosage form. In an embodiment, the dosage form can be a solid dosage form, a liquid dosage form, or a semisolid dosage form. In an embodiment, the dosage form can include, for example, a pill, an orally disintegrating tablet, a chewable tablet, a swallowing tablet, a capsule, a caplet, a drink, a syrup, a gel, or a strip.
[0053] In an embodiment, the dosage form is a vaginal ring or a patch, such that the vaginal ring or patch can be removed during any period where the active ingredient(s) are not administered in the methods disclosed herein. For example, in a continuous regimen, a patch or ring can be removed after a defined period (e.g., 90 days) and another ring or patch can be applied right away so as to provide uninterrupted administration of the active ingredient(s).
[0054] In an embodiment, the contraception method includes a kit comprising a package containing daily dosages of the estrogen with or without the progestogen, and the optional placebo, as described herein.
[0055] In an embodiment, the package may contain daily dosages of: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28-day cycle (e.g., about 20 to about 27 tablets, each including the aforementioned amounts of the estrogen and the progestogen, in, for example, a blister pack); and (b) a placebo (e.g., placebo tablet(s) in, for example, the blister pack, or, alternatively, empty blister(s) in the blister pack) for the remainder of the 28-day cycle. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0056] In an embodiment, the kit further comprises instructions for administering the daily dosages according to the method of contraception for a female in need thereof, being a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28- day cycle; and (b) a placebo for the remainder of the 28 -day cycle.
[0057] In an embodiment, the package may contain daily dosages of: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 28 consecutive days up to 84 consecutive days (e.g., up to 84 tablets, each including the aforementioned amounts of the estrogen and the progestogen, in, for example, a blister pack, or multiple blister packs); and (b) a placebo (e.g., placebo tablet(s) in, for example, the blister pack, or, alternatively, empty blister(s) in the blister pack) for the up to 7 days. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0058] In an embodiment, the kit further comprises instructions for administering the daily dosages according to the method of contraception for a female in need thereof, being a cyclic monophasic regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for at least 28 consecutive days up to about 84 consecutive days of a cycle; and (b) a placebo for about 1 to about 7 days following step (a) for the remainder of the cycle.
[0059] In an embodiment, the package may contain daily dosages of: (a) phase I composition comprising about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 26 consecutive days of a 28-day cycle (e.g., about 20 to about 26 tablets, each including the aforementioned amounts of the estrogen and the progestogen, in, for example, a blister pack); (b) phase II composition comprising about 1 mcg to less than about 5 mcg of the estrogen, without a progestogen, for about 1 to about 6 consecutive days of the 28-day cycle following the administration of the phase I composition, such that at least one day remains in this 28-day cycle (e.g., about 1 to 6 tablets, each including the aforementioned amount of the estrogen and no progestogen, in, for example, the blister pack); and (c) a placebo (e.g., placebo tablet(s), or, alternatively, empty blister(s) in the blister pack) for the remainder of the 28-day cycle. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the phase I composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the phase I composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel. In an embodiment, the phase II composition comprises about 2.5 mcg of an estrogen. In an embodiment, the phase II composition comprises about 2.5 mcg of ethinyl estradiol.
[0060] In an embodiment, the kit further comprises instructions for administering the daily dosages according to the method of contraception for a female in need thereof, being a cyclic multiphasic regimen which includes administering, daily, the following compositions: (a) phase I composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for about 20 to about 26 consecutive days of a 28-day cycle; (b) phase II composition comprising about 1 mcg to less than about 5 mcg of the estrogen in the absence of the progestogen for about 1 to about 6 consecutive days of the 28-day cycle following the administration of the phase I composition,; and (c) a placebo for the remainder of the 28-day cycle following the administration of the phase II composition.
[0061] In an embodiment, the package may contain daily dosages of: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen for a continuous regimen. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 1 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of ethinyl estradiol and about 1 mg of norethindrone acetate. In an embodiment, the composition comprises about 2.5 mcg of an estrogen and about 0.075 to about 0.15 mg of a progestogen. In an embodiment, the composition comprises about 2.5 mcg of an ethinyl estradiol and about 0.075 to about 0.15 mg of a desogestrel.
[0062] In an embodiment, the kit further comprises instructions for administering the daily dosages according to the method of contraception for a female in need thereof, being a monophasic continuous regimen which includes administering, daily, the following: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and about 0.075 mg to about 5 mg of a progestogen.
[0063] While the methods/regimens as disclosed herein are practiced by administration of the compositions in a numeric sequence with the estrogen/progestin containing composition(s) being used first, optionally, the estrogen only composition(s) or the optional placebo being used thereafter as discussed above, if packaging and/or other requirements dictate, the method and kit described herein can be employed as part of a larger scheme for contraception, or treatment of gynecological disorders. Reasonable variations, such as those which would occur to one of ordinary skill in the art, can be made herein without departing from the scope of the invention. For example, variations in time and dosage can be tolerated when medical considerations so dictate.
EXAMPLES
[0064] Specific embodiments will now be demonstrated by reference to the following examples. It should be understood that these examples are disclosed solely by way of illustrating the invention and should not be taken in any way to limit the scope of the present invention.
EXAMPLE 1
[0065] The compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
[0066] Table 1
[0067] The norethindrone acetate (NA) and ethinyl estradiol (EE) are well known and readily available.
EXAMPLE 2
[0068] The compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
[0069] Table !
[0070] The norethindrone acetate (NA) and ethinyl estradiol (EE) are well known and readily available. EXAMPLE 3
[0071] The compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
[0072] Table 3
[0073] The norethindrone acetate (NA) and ethinyl estradiol (EE) are well known and readily available.
EXAMPLE 4
[0074] The compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
[0075] Table 4
[0076] The norethindrone acetate (NA) and ethinyl estradiol (EE) are well known and readily available. In an embodiment, each of the phase I composition and phase II compositions are administered as oral dosage forms. In an embodiment, phase I composition is administered as a vaginal ring or a patch and the phase II composition is administered as an oral dosage form.
EXAMPLE 5
[0077] The compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table. [0078] Table 5
[0079] The norethindrone acetate (NA) and ethinyl estradiol (EE) are well known and readily available.
EXAMPLE 6
[0080] The compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
[0081] Table 6
[0082] The norethindrone acetate (NA) and ethinyl estradiol (EE) are well known and readily available.
EXAMPLE 7
[0083] The compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
[0084] Table 7
[0085] The norethindrone acetate (NA) and ethinyl estradiol (EE) are well known and readily available. EXAMPLE 8
[0086] The compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
[0087] Table 8
[0088] The norethindrone acetate (NA) and ethinyl estradiol (EE) are well known and readily available.
EXAMPLE 9
[0089] The compositions employed in accordance with the invention will have the administration times and drug contents set forth in the following table.
[0090] Table 9
[0091] The norethindrone acetate (NA) and ethinyl estradiol (EE) are well known and readily available. For example, continuous regimen can be administered for up to 40 years. [0092] In an embodiment, the regimens in the above Examples are administered daily via oral dosage forms. In an embodiment, norethindrone acetate (NA) and/or ethinyl estradiol (EE) in the Examples are administered via a vaginal ring or a patch.
[0093] For instance, in a multiphasic regimen, phase I is administered via a vaginal ring or a patch and phase II is administered via an oral dosage form. Alternatively, each phase is administered via a vaginal ring or a patch.
[0094] In an embodiment, if a vaginal ring is used, the vaginal ring may be removed after a certain period of time (e.g., 30 days or 90 days) followed by immediately inserting a new vaginal ring. In an embodiment, if a patch is used, the patch may be removed after a certain period of time (e.g., 30 days or 90 days) followed by immediately applying a new patch. [0095] It should be noted that the tables are presented for illustrative purposes only. The substitution of functionally equivalent amounts and kinds of reagent(s) in these schemes is contemplated.

Claims

WHAT IS CLAIMED IS:
1. A regimen of contraception for a female in need thereof comprising: a) administering to the female, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28-day cycle; and b) administering to the female, daily, a placebo for a remainder of the 28-day cycle.
2. A regimen of contraception for a female in need thereof comprising: a) administering to the female, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 28 consecutive days up to 81 consecutive days of a cycle; and then b) administering to the female, daily, a placebo for about 1 to about 7 days consecutive days of the cycle.
3. A regimen of contraception for a female in need thereof comprising: a) administering to the female, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 26 consecutive days of a 28-day cycle; and b) administering to the female, daily, about 1 mcg to less than about 5 mcg of the estrogen in the absence of the progestogen for about 1 to about 6 consecutive days, of the 28-day cycle following the step a); and c) administering to the female, daily, a placebo for a remainder of the 28-day cycle.
4. A regimen of contraception for a female in need thereof comprising: continuously administering to the female, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen.
5. The regimen of claim 1, wherein the estrogen and the progestogen are administered for 27 consecutive days, or 26 consecutive days, or 25 consecutive days, or 24 consecutive days, or 23 consecutive days, or 22 consecutive days, or 21 consecutive days, or 20 consecutive days.
23 The regimen of claim 2, wherein the estrogen and the progestogen are administered for 42 consecutive days, or 56 consecutive days, or 63 consecutive days, or 81 consecutive days. The regimen of claim 3, wherein the estrogen and the progestogen in step a) are administered for 26 consecutive days, or 25 consecutive days, or 24 consecutive days, or 23 consecutive days, or 22 consecutive days, or 21 consecutive days. The regimen of claim 3, wherein the estrogen in the absence of the progestogen in the step b) is administered for 1 day, or 2 consecutive days, or 3 consecutive days, or 4 consecutive days, or 5 consecutive days, or 6 consecutive days. The regimen of any of claims 1, 3, 5, 7 or 8, wherein following the completion of the 28-day cycle, a new 28-day cycle begins. The regimen of claim 2, wherein following the completion of the cycle, a new cycle begins. The regimen of any one of claims 1 -3, wherein a daily amount of the estrogen administered in the step a) is about 1 mcg, or about 1. 1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2.1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4. 1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg. The regimen of claim 3, wherein a daily amount of the estrogen administered in the step b) is about 1 mcg, or about 1.1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2.1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4.1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg. The regimen of claim 4, wherein a daily amount of the estrogen is about 1 mcg, or about 1. 1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2.1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4.1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg. The regimen of claim 4 or 13, wherein a daily amount of the progestogen is about 0.075 mg, or 0.1 mg, or 0.15 mg, or about 0.2 mg, or 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1.1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg. The regimen of any one of claims 1-3 or 11, wherein a daily amount of the progestogen administered in the step a) 0.075 mg, or 0.1 mg, or 0.15 mg, or about 0.2 mg, or 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1.1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg. The regimen of any of claims 1-3, 5-12 or 15, wherein in the step a), the estrogen and the progestogen are administered in a single dosage form. The regimen of claim 4, wherein the estrogen and the progestogen are administered in a single dosage form. The regimen of claim 16 or 17, wherein the single dosage form is selected from an orally disintegrating tablet, a chewable tablet, a swallowing tablet, or a strip. The regimen of any of the preceding claims, wherein the estrogen is ethinyl estradiol. The regimen of any of the preceding claims, wherein the progestogen is norethindrone acetate or desogestrel. The regimen of any of the preceding claims, wherein the regimen is for treating one or more symptoms associated with endometriosis or fibroids in the female in need thereof. The regimen of claim 21, wherein the female is not administered a gonadotropinreleasing hormone antagonist or a gonadotropin-releasing hormone agonist. A regimen for treating one or more symptoms of endometriosis or fibroids for a female in need thereof comprising: a) administering to the female, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 27 consecutive days of a 28-day cycle; and b) administering to the female, daily, a placebo for a remainder of the 28-day cycle. A regimen for treating one or more symptoms of endometriosis or fibroids for a female in need thereof comprising: a) administering to the female, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 28 consecutive days up to 84 consecutive days of a cycle; and then b) administering to the female, daily, a placebo for about 1 to about 7 days consecutive days of the cycle. A regimen for treating one or more symptoms of endometriosis or fibroids for a female in need thereof comprising: a) administering to the female, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen for about 20 to about 26 consecutive days of a 28-day cycle; and b) administering to the female, daily, about 1 mcg to less than about 5 mcg of the estrogen in the absence of the progestogen for about 1 to about 6 consecutive days, of the 28-day cycle following the step a); and
26 c) administering to the female, daily, a placebo for a remainder of the 28-day cycle.
26. A regimen for treating one or more symptoms of endometriosis or fibroids for a female in need thereof comprising: continuously administering to the female, daily, about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen.
27. The regimen of claim 23, wherein the estrogen and the progestogen are administered for 27 consecutive days, or 26 consecutive days, or 25 consecutive days, or 24 consecutive days, or 23 consecutive days, or 22 consecutive days, or 21 consecutive days, or 20 consecutive days.
28. The regimen of claim 24, wherein the estrogen and the progestogen are administered for 42 consecutive days, or 56 consecutive days, or 63 consecutive days, or 81 consecutive days.
29. The regimen of claim 25, wherein the estrogen and the progestogen in step a) are administered for 26 consecutive days, or 25 consecutive days, or 24 consecutive days, or 23 consecutive days, or 22 consecutive days, or 21 consecutive days.
30. The regimen of claim 25, wherein the estrogen in the absence of the progestogen in step b) is administered for 1 day, or 2 consecutive days, or 3 consecutive days, or 4 consecutive days, or 5 consecutive days, or 6 consecutive days.
31. The regimen of any of claims 23, 25, 27, 29, or 30, wherein following the completion of the 28-day cycle, a new 28-day cycle begins.
32. The regimen of claim 24, wherein following the completion of the cycle, a new cycle begins.
33. The regimen of any of claims 23-25, wherein a daily amount of the estrogen administered in the step a) is about 1 mcg, or about 1. 1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2.1 mcg or about
27
2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4. 1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg. The regimen of claim 25, wherein a daily amount of the estrogen administered in the step b) is about 1 mcg, or about 1.1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2.1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4.1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg. The regimen of claim 26, wherein a daily amount of the estrogen is about 1 mcg, or about 1. 1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2.1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4.1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg. The regimen of claim 26 or 35, wherein a daily amount of the progestogen is about 0.075 mg, or 0.1 mg, or 0.15 mg, or about 0.2 mg, or 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1.1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg. The regimen of any of claims 23-25 or 33, wherein a daily amount of the progestogen administered in the step a) is about 0.075 mg, or 0. 1 mg, or 0.15 mg, or about 0.2 mg, or 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or
28 about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1.1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg. The regimen of any of claims 23-25, or 27-33, wherein in the step a), the estrogen and the progestogen are administered in a single dosage form. The regimen of claim 24, wherein the estrogen and the progestogen are administered in a single dosage form. The regimen of claim 38 or 39, wherein the single dosage form is selected from an orally disintegrating tablet, a chewable tablet, a swallowing tablet, or a strip. The regimen of any of claims 21-40 wherein the estrogen is ethinyl estradiol. The regimen of any of claims 21-40, wherein the progestogen is norethindrone acetate or desogestrel. A contraceptive kit comprising a package comprising daily dosages of: (a) a composition comprising about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen, and, optionally, (b) a placebo. The kit of claim 43, wherein the kit comprises about 20 to about 84 doses of the active composition. The kit of claim 43 or 44, wherein the active composition comprises about 1 mcg, or about 1. 1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2.1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4.1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg of the estrogen. The kit of claim 43 or 44, wherein the active composition comprises about 0.075 mg, or 0.1 mg, or 0.15 mg, or about 0.2 mg, or 0.25 mg, or about 0.3 mg, or about 0.4 mg,
29 or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1.1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg of the progestogen. The kit of any one of claims 43-46, wherein the estrogen in the active composition is ethinyl estradiol. The kit of any one of claims 43-46, wherein the progestogen in the active composition is norethindrone acetate or desogestrel. A contraceptive kit comprising a package comprising daily dosages of: (a) a phase I composition comprising about 1 mcg to less than about 5 mcg of an estrogen and 0.075 mg to about 5 mg of a progestogen, (b) a phase II composition comprising about 1 mcg to less than about 5 mcg of an estrogen in the absence of the progestogen, and optionally (c) a placebo. The kit of claim 49, wherein the kit comprises about 20 to about 26 doses of the phase I composition. The kit of claim 49, wherein the kit comprises about 1 to about 6 doses of the phase II composition. The kit of any one of claims 49-51, wherein the phase I composition comprises about 1 mcg, or about 1. 1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2.1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4.1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg of the estrogen, and about 0.075 mg, or 0.1 mg, or 0. 15 mg, or about 0.2 mg, or 0.25 mg, or about 0.3 mg, or about 0.4 mg, or about 0.5 mg, or about 0.6 mg, or about 0.7 mg, or about 0.8 mg, or about 0.9 mg, or about 1.0 mg, or about 1. 1 mg, or about 1.2 mg, or about 1.3 mg, or about 1.4 mg, or about 1.5 mg of the progestogen.
30 The kit of any one of claims 49-51, wherein the estrogen in the phase I composition is ethinyl estradiol. The kit of any one of claims 49-51, the progestogen in the phase I composition is norethindrone acetate or desogestrel. The kit of any one of claims 49-51, wherein the phase II composition comprises about 1 mcg, or about 1. 1 mcg, or about 1.2 mcg, or about 1.3 mcg, or about 1.4 mcg, or about 1.5 mcg, or about 1.6 mcg, or about 1.7 mcg, or about 1.8 mcg, or about 1.9 mcg, or about 2.0 mcg, or about 2.1 mcg or about 2.2 mcg, or about 2.3 mcg, or about 2.4 mcg, or about 2.5 mcg, or about 2.6 mcg, or about 2.7 mcg, or about 2.8 mcg, or about 2.9 mcg, or about 3.0 mcg, or about 3.1 mcg or about 3.2 mcg, or about 3.3 mcg, or about 3.4 mcg, or about 3.5 mcg, or about 3.6 mcg, or about 3.7 mcg, or about 3.8 mcg, or about 3.9 mcg, or about 4.0 mcg or about 4.1 mcg, or about 4.2 mcg, or about 4.3 mcg, or 4.4 mcg, or about 4.5 mcg of the estrogen in the absence of the progestogen. The kit of claim 49-51, wherein the estrogen in the phase II composition is ethinyl estradiol.
31
EP22782576.7A 2021-09-07 2022-09-07 Contraceptive regimen including reduced level of estrogen Pending EP4398913A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163241178P 2021-09-07 2021-09-07
US17/483,199 US20230070977A1 (en) 2021-09-07 2021-09-23 Contraceptive regimen including reduced level of estrogen
PCT/IB2022/058420 WO2023037264A1 (en) 2021-09-07 2022-09-07 Contraceptive regimen including reduced level of estrogen

Publications (1)

Publication Number Publication Date
EP4398913A1 true EP4398913A1 (en) 2024-07-17

Family

ID=83506501

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22782576.7A Pending EP4398913A1 (en) 2021-09-07 2022-09-07 Contraceptive regimen including reduced level of estrogen

Country Status (3)

Country Link
EP (1) EP4398913A1 (en)
CA (1) CA3234836A1 (en)
WO (1) WO2023037264A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US5888543A (en) 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US20020177580A1 (en) * 2001-05-23 2002-11-28 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
ATE410171T1 (en) 2003-11-14 2008-10-15 Warner Chilcott Co Inc GRADUATED ESTROGEN CONTRACEPTIVES
SG166107A1 (en) 2005-06-29 2010-11-29 Warner Chilcott Co Llc Quadraphasic continuous graduated estrogen contraceptive
US20230135376A1 (en) * 2020-06-25 2023-05-04 Millicent Pharma Limited Multiphasic contraceptive and/or hormone replacement therapy

Also Published As

Publication number Publication date
CA3234836A1 (en) 2023-03-16
WO2023037264A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
US5898032A (en) Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US8415332B2 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Kailas et al. Contraception during perimenopause
CZ288062B6 (en) Preparation for woman contraception
CA2582530A1 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US20030018018A1 (en) Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
AU781835B2 (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
EP4398913A1 (en) Contraceptive regimen including reduced level of estrogen
US20230070977A1 (en) Contraceptive regimen including reduced level of estrogen
US20230135376A1 (en) Multiphasic contraceptive and/or hormone replacement therapy
WO1999025360A2 (en) Progestogen-antiprogestogen regimens
AU2006215818A1 (en) Contraceptive pharmaceutical preparation
Ahrendt et al. Estrogen Free Contraception: progestin-only systems
Abadi et al. The role of low dosage combined oral contraceptive pill in perimenopausal women
Contraceptives Progestogen-Only Contraception
Sedlecky et al. Management with Female Contraceptives of Issues Associated
Castracane et al. Changes in oral contraceptive design since the original release. Commentary on The biological history of the Pill by Roy O. Greep
Ahrendt et al. Reproduktionsmedizin und Endokrinologie
Kovacs Luteal contraception
Narendran Hormonal Contraception in Female: Advantages and Disadvantages
A Garside et al. An update on developments in female hormonal contraception
Savage Contraception During Perimenopause
Sedlecky et al. Management of Issues Associated with Female Contraceptives
Hickey Drugs for Breakthrough Bleeding Due to Hormonal Therapies
Schreiber et al. Revised 11 January 2018

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240405

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR